Precision BioSciences (DTIL) News Today $4.45 -0.38 (-7.87%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$4.49 +0.04 (+0.90%) As of 07/11/2025 06:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock DTIL Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Elie Saab Blends 19th-Century Romance With Red Carpet Precision in Fall CoutureJuly 9, 2025 | msn.comPrecision BioSciences, Inc. (NASDAQ:DTIL) CFO Sells $63,163.02 in StockJuly 9, 2025 | insidertrades.comInsider Selling: Precision BioSciences, Inc. (NASDAQ:DTIL) CFO Sells 14,827 Shares of StockJuly 8, 2025 | marketbeat.comPrecision BioSciences, Inc. (DTIL) - Yahoo FinanceJuly 5, 2025 | finance.yahoo.comTransDigm to Buy Simmonds Precision Products From RTX for $765 MillionJune 30, 2025 | marketwatch.comFounder of Neuralink rival Precision Neuroscience reveals what people often get wrong about brain-implant surgeryJune 29, 2025 | msn.comPrecision BioSciences Receives FDA Rare Pediatric Disease Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy - MorningstarJune 26, 2025 | morningstar.comMDTIL - Precision BioSciences Inc Key Metrics - MorningstarJune 26, 2025 | morningstar.comMPrecision BioSciences Gets FDA's Rare Pediatric Disease Designation For PBGENE-DMD - NasdaqJune 26, 2025 | nasdaq.comDTIL Precision BioSciences, Inc. - Seeking AlphaJune 26, 2025 | seekingalpha.comPrecision BioSciences stock jumps after FDA grants rare pediatric designationJune 25, 2025 | za.investing.comPrecision BioSciences Receives FDA Rare Pediatric Disease Designation for PBGENE-DMD for the Treatment of Duchenne Muscular DystrophyJune 25, 2025 | businesswire.com46,929 Shares in Precision BioSciences, Inc. (NASDAQ:DTIL) Purchased by Squarepoint Ops LLCJune 9, 2025 | marketbeat.comCitadel Advisors LLC Increases Stock Holdings in Precision BioSciences, Inc. (NASDAQ:DTIL)June 2, 2025 | marketbeat.comPrecision BioSciences' (DTIL) "Buy" Rating Reiterated at HC WainwrightMay 23, 2025 | marketbeat.comUncovering Potential: Precision BioSciences's Earnings PreviewMay 16, 2025 | benzinga.comPrecision BioSciences Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 15, 2025 | businesswire.comPrecision BioSciences Accelerates Development of PBGENE-DMD Within its Wholly Owned Organic Pipeline and Highlights Pre-clinical Evidence at the American Society of Gene and Cell Therapy (ASGCT) Annual MeetingMay 14, 2025 | businesswire.comPrecision BioSciences Q1 2025 Earnings PreviewMay 14, 2025 | msn.comPrecision BioSciences, Inc. (NASDAQ:DTIL) Shares Sold by Alyeska Investment Group L.P.May 9, 2025 | marketbeat.comPrecision BioSciences to Report First Quarter 2025 Results on May 15, 2025May 8, 2025 | businesswire.comPrecision BioSciences (DTIL) to Release Earnings on MondayMay 7, 2025 | marketbeat.comPrecision BioSciences Announces Presentation of Initial Safety Data from the Phase 1 ELIMINATE-B Trial Evaluating PBGENE-HBV at the 2025 European Association for the Study of the Liver Congress (EASL)May 7, 2025 | businesswire.comPrecision BioSciences (DTIL) Receives a Buy from H.C. WainwrightMay 3, 2025 | theglobeandmail.comPrecision BioSciences Announces Multiple Presentations for In Vivo Gene Editing Programs at the American Society of Gene and Cell Therapy (ASGCT) Annual MeetingMay 1, 2025 | businesswire.comLynx1 Capital Management LP Makes New Investment in Precision BioSciences, Inc. (NASDAQ:DTIL)April 29, 2025 | marketbeat.comPrecision BioSciences, Inc. (NASDAQ:DTIL) Short Interest UpdateApril 22, 2025 | marketbeat.comPrecision BioSciences stock rises following FDA Fast Track designationApril 15, 2025 | in.investing.comPrecision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis BApril 15, 2025 | businesswire.comPrecision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare ConferenceApril 1, 2025 | businesswire.comInsider Buying: Precision BioSciences, Inc. (NASDAQ:DTIL) Director Buys 3,250 Shares of StockMarch 28, 2025 | insidertrades.comPrecision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business UpdateMarch 26, 2025 | businesswire.comAssessing Precision BioSciences: Insights From 4 Financial AnalystsMarch 21, 2025 | nasdaq.comPrecision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025March 21, 2025 | businesswire.comPrecision BioSciences Presents Preclinical Safety and Efficacy Data Supporting Repeat Dosing of PBGENE-HBV With a Goal of Curing Chronic Hepatitis B at the Global Hepatitis Summit 2025March 20, 2025 | businesswire.comPrecision BioSciences presents preclinical data from PBGENE-DMD programMarch 19, 2025 | markets.businessinsider.comPrecision BioSciences Presents Preclinical Efficacy and Durability Data on PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy (DMD) at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific ConferenceMarch 19, 2025 | businesswire.comFDA clears Precision BioSciences’ IND for PBGENE-HBV to treat HBVMarch 17, 2025 | markets.businessinsider.comPrecision BioSciences Announces Clearance of Investigational New Drug Application by the U.S. FDA for First-in-Class PBGENE-HBV Designed to Eliminate Root Cause of Chronic Hepatitis BMarch 17, 2025 | businesswire.comPrecision & TG Therapeutics: Unlocking Value With ARCUS, BRIUMVI And Azer-CelMarch 15, 2025 | seekingalpha.comPrecision BioSciences Announces Oral Presentation at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific ConferenceFebruary 24, 2025 | businesswire.comH.C. Wainwright Maintains Buy on Precision BioSciences StockFebruary 21, 2025 | uk.investing.comPrecision BioSciences Touts Encouraging Initial Safety And Antiviral Activity Of Hepatitis B Treatment CandidateFebruary 19, 2025 | benzinga.comPrecision BioSciences announces initial results from ELIMINATE-B trialFebruary 19, 2025 | markets.businessinsider.comPrecision Bio gains on early Phase 1 data for Hep B candidateFebruary 19, 2025 | msn.comPrecision BioSciences Announces Initial Safety and Antiviral Activity of PBGENE-HBV in the ELIMINATE-B Clinical TrialFebruary 19, 2025 | businesswire.comMaxCyte Enters Strategic License Agreement with TG Therapeutics for Cell-Based Therapy DevelopmentFebruary 12, 2025 | quiverquant.comQPrecision BioSciences Strengthens Senior Leadership Team to Drive Multiple In Vivo Gene Editing ProgramsJanuary 29, 2025 | businesswire.comPrecision BioSciences, Inc. (NASDAQ:DTIL) Insider Sells $49,274.73 in StockJanuary 23, 2025 | insidertrades.comPrecision Biosciences' general counsel sells shares worth $42,765January 22, 2025 | msn.com Get Precision BioSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for DTIL and its competitors with MarketBeat's FREE daily newsletter. Email Address DTIL Media Mentions By Week DTIL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DTIL News Sentiment▼0.500.99▲Average Medical News Sentiment DTIL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DTIL Articles This Week▼52▲DTIL Articles Average Week Get Precision BioSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for DTIL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Organigram Global News ProKidney News Alumis News Eledon Pharmaceuticals News Cybin News Instil Bio News Puma Biotechnology News Voyager Therapeutics News Tiziana Life Sciences News I-Mab News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:DTIL) was last updated on 7/13/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Precision BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Precision BioSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DTIL Stock Alerts